

### Hypertension Detection and Follow-up Program Mainstream, Final, and Associated Publications

1. **The new national cooperative Hypertension Detection and Follow-up Program.** Stamler J, Berkson DM, Gosch FC, Hilker RJ, Lindberg HA, Schoenberger JA, Shekelle RB, Stamler R. *Chicago Medicine* 1973; 76.
2. **Medical News: Hypertension study enters second phase.** *JAMA* 1973; 224:461-462.
3. **Hypertension in the inner city. II. Detection and follow-up.** Finnerty FA, Shaw LW, Himmelsback CK. *Circulation* 1973; 47:76-78.
4. **The Hypertension Detection and Follow-up Program.** Remington RD, on behalf of the HDFP Cooperative Group. *INSERM* 1973; 21:185-194.
5. **Evaluation of performance of selected devices for measuring blood pressure.** Labarthe DR, Hawkins CM, Remington RD. *American Journal of Cardiology* 1973; 32:546-553.
6. **High blood pressure: its care and consequences in urban centers.** Apostolides A, Hebel JR, McDill MS, Henderson MM. *Inter J Epidemiol* 1974; 3:105-118.
7. **A study of hypertension in a black urban community: preliminary epidemiologic findings.** Henderson MM, Apostolides A, Entwisle G, Hebel JR. *Prev Med* 1974; 3:334-343. (Local Paper-Baltimore)
8. **The Hypertension Detection and Follow-up Program.** Langford HG, Payne G, Remington RD, Stamler J. In *Epidemiology and Control of Hypertension*, O. Paul (editor), Stratton Intercontinental Medical Book Corporation, New York, 1975; pp:663-672. (Paper 1A)
9. **Computer-aided management of hypertensive patients.** Wassertheil-Smoller S, Bell B, Blaufox MD. *Medical Care* 1975; 13:1044-1054. (Local Paper-New York)
10. **Adherence and blood pressure response to hypertension treatment.** Stamler R, Gosch FC, Stamler J, Ticho S, Civinelli J, Restivo B, Pritchard D, Fine D. *Lancet* 1975; ii:1227-1230.
11. **The Hypertension Detection and Follow-up Program.** HDFP Cooperative Group (Borhani NO, Kass EH, Langford HG, Payne GH, Remington RD, Stamler J). *Preventive Medicine* 1976; 5:207-215. (Paper 1)
12. **Planning case-finding activities for a community hypertension control program.** Wassertheil-Smoller S, Blaufox MD. *Bull NY Acad Med* 1976; 52:648-656. (Local Paper-New York)
13. **Blood pressure studies in 14 communities: A two-stage screen for hypertension.** HDFP Cooperative Group (Castle CH, Daugherty S, Detels R, Hawkins CM, Krishan I, Oberman A, Wassertheil-Smoller S). *JAMA* 1977; 237:2385-2391. (Paper 2)
14. **The Hypertension Detection and Follow-up Program: A progress report.** HDFP Cooperative Group. *Circulation Research* 1977; 40(Suppl I):106-109. (Paper 26)
15. **Race, education and prevalence of hypertension.** HDFP Cooperative Group: Heymsfield S, Kraus JF, Lee ES, McDill M, Stamler R, Watson R. *American Journal of Epidemiology* 1977; 106:351-361. (Paper 5A)
16. **Target organ damage in black hypertensives.** Entwisle G, Apostolides AY, Hebel JR, Henderson MM. *Circulation* 1977; 55:792-796. (Local Paper-Baltimore)
17. **Echocardiograph and essential hypertension.** Schlant RC, Felner JL, Heymsfield SB, Gilbert CA, Shulman NB, Tuttle EP, Blumenstein BA. *Cardiov Med* 1977; 2:477-490. (Local Paper-Atlanta)
18. **Mild hypertensives in the HDFP.** HDFP Cooperative Group: Apostolides A, Blaufox MD, Borhani NO, Cutter G, Daugherty S, Lewin AJ, Polk BF. *Ann NY Acad Sci* 1978; 304:254-266. (Paper 25)
19. **Improving trend in hypertension control in a black inner city community.** Apostolides AY, Entwisle G, Quillet R, Hebel JR. *American Journal of Epidemiology* 1978; 107:113-119. (Local Paper-Baltimore)
20. **A hypertension control program based on the workplace: Report on the Chicago center.** Stamler R, Gosch FC, Stamler J, Lindberg HA, and Hilker RJ. *Journal of Occupational Medicine* 1978; 20:618-625. (Paper 18)
21. **Patient participation in a hypertension control program.** HDFP Cooperative Group: Apostolides A, Schnaper H, Stamler R, Taylor J, Tyler M, Wassertheil-Smoller S. *JAMA* 1978; 239:1507-1514. (Paper 10)
22. **Variability of blood pressure and the results of screening in the HDFP.** HDFP Cooperative Group: Cutter G, Hebel JA, Labarthe D, Oberman A, Prineas R, Varady P. *Journal of Chronic Diseases* 1978; 31:651-667. (Paper 9)
23. **The Hypertension Detection and Follow-up Program.** Borhani NO. In *Hypertension: Determinants, Complications, and Intervention*, G. Onesti and C.R. Klimt-editors. Grune & Stratton, Inc., NY, 1979; pp:405-414. (Paper 27)
24. **Therapeutic control of blood pressure in the HDFP.** HDFP Cooperative Group. Blaufox MD, Curb JD, Kralios A, Polk BF, Tyler M. *Preventive Medicine* 1979; 8:2-13. (Paper 4)
25. **Recent status of detection, treatment and**

- control of hypertension in the community.** Wassertheil-Smoller S, Apostolides A, Miller M, Oberman A, Thom T, on behalf of the Hypertension Detection and Follow-up Program. *Journal of Community Health* 1979; 5:82-93. (Paper 20)
26. **Five-year findings of the HDFP. I. Reduction in mortality of persons with high blood pressure, including mild hypertension.** HDFP Cooperative Group. *JAMA* 1979; 242:2562-2571. (Final Paper 1)
27. **Five-year findings of the HDFP. II. Mortality by race-sex and age.** HDFP Cooperative Group. *JAMA* 1979; 242:2572-2577. (Final Paper 2)
28. **Estimated community impact of hypertension control in a high-risk population.** Quillet RP, Apostolides AY, Entwisle G, Hebel JR. *Am J Epidemiol* 1979; 109:531-538. (Local Paper-Baltimore)
29. **Follow-up of hypertension screening and methodology for improving blood pressure normalization.** Blaufox MD, Wassertheil-Smoller S. *NY St J Med* 1979; 79:231-235. (Local Paper-New York)
30. **Mortality surveillance in collaborative trials.** Cutter G, Heyden S, Kasteler J, Kraus JF, Lee ES, Shipley T, Stromer M, on behalf of the Hypertension Detection and Follow-up Program. *American Journal of Public Health* 1980; 70:394-400. (Paper 13)
31. **Impact of hypertension information on high blood pressure control between 1973 and 1978.** Apostolides AY, Cutter G, Kraus JF, Oberman A, Blaszkowski T, Borhani NO, Entwisle G. *Hypertension* 1980; 2:708-713. (Impact of Hypertension Information Study Paper 1)
32. **Residential mobility and long-term treatment of hypertension.** Cowan L, Detels R, Farber M, Lee ES, McCray G, O'Flynn S, Parnell MJ, on behalf of the HDFP Cooperative Group. *J Comm Hlth* 1980; 5:159-166. (Paper 5B)
33. **Application of survival analysis techniques to evaluation of factors affecting compliance in a clinical trial of hypertension control.** Smith EO, Hardy RJ, Cutter GR, Curb JD, Hawkins CM. *Controlled Clinical Trials* 1980; 1:59-69. (Paper 54A)
34. **Two-compartment Markov regression analysis.** Smith EO, Hardy J, Cooper CJ, Hawkins CM. *Computer Programs in Biomedicine* 1980; 12:129-149. (Paper 54B)
35. **A two-compartment regression model applied to compliance in a hypertension treatment program.** Smith EO, Hardy RJ, Cutter GR. *J Chron Dis* 1980; 33:645-651. (Paper 54C)
36. **Within-person variability in diastolic blood pressure for a cohort of normotensives.** Hebel JR, Apostolides AY, Dischinger G, Entwisle G, Su S. *J Chron Dis* 1980; 33:745-750. (Local Paper-Baltimore)
37. **Lessons from the HDFP.** Daugherty SA. *Urban Health* 1981; May:28-30.
38. **Hypertension incidence in an inner-city black population.** Dischinger G, Apostolides AY, Entwisle G, Hebel JR. *J Chron Dis* 1981; 34:405-413. (Local Paper-Baltimore)
39. **Five-year findings of the HDFP. III. Reduction in stroke incidence among persons with high blood pressure.** HDFP Cooperative Group. *JAMA* 1982; 247:633-638. (Final Paper 5)
40. **The effect of treatment on mortality in "mild" hypertension—results of the HDFP.** HDFP Cooperative Group. *New England Journal of Medicine* 1982;307: 976-980. (Final Paper 2A)
41. **Reserpine and breast cancer in the HDFP.** Curb JD, Hardy RJ, Labarthe DR, Borhani NO, Taylor JO. *Hypertension* 1982; 4:307-311. (Paper 56)
42. **Correlates of attendance and compliance in the HDFP.** Shulman N, Cutter G, Daugherty R, Sexton M, Pauk G, Taylor MJ, Tyler M. *Controlled Clinical Trials* 1982; 3:13-27. (Paper 8)
43. **Clinic attendance in the HDFP.** Smith EO, Curb JD, Hardy RJ, Hawkins CM, Tyroler HA. *Hypertension* 1982; 4:710-715. (Paper 54)
44. **Three-year incidence of hypertension in thirteen US communities.** Apostolides A, Cutter G, Daugherty SA, Detels R, Kraus J, Wassertheil-Smoller S, Ware J. *Preventive Medicine* 1982; 11:487-499. (Paper 38)
45. **Relationship of demographic characteristics of interviewers to blood pressure measurements.** Kraus JF, Conley A, Hardy RJ, Sexton M, Sweezey Z. *J Comm Hlth* 1982; 8:3-12. (Paper 15)
46. **Comparison of self-reported and measured height and weight.** Palta M, Prineas RJ, Berman R, Hannan P. *Am J Epidemiol* 1982; 115:223-230. (Local Paper-Minneapolis)
47. **Race, education and five-year mortality in HDFP stratum I referred-care males.** Tyroler HA. Chapter in *Mild Hypertension: Recent Advances*. R. Gross and T. Strasser editors. Raven Press, NY, 1983; pp:163-175. (Paper 28A)
48. **Further analyses of the HDFP.** Langford HG. In *Mild Hypertension: Recent Advances*, F. Gross, T. Strasser (Editors). Raven Press, New York, 1983; pp: 307-313.
49. **Predictive values of routine blood pressure**

- measurements in screening for hypertension. Rosner B, Polk BF. *Am J Epidemiol* 1983; 117:429-442. (Local Paper-Boston)
50. **The impact of selected indices of antihypertensive therapy on all cause mortality.** Hardy RJ, Hawkins CM. *Am J Epidemiol* 1983; 117:566-574. (Paper 76)
  51. **Nosological coding of cause of death.** Curb JD, Babcock C, Pressel S, Tung B, Remington RD. *American Journal of Epidemiology* 1983; 118:122-128. (CCCT Paper)
  52. **Prediagnostic serum selenium and risk of cancer.** Willett WC, Polk BF, Morris JS, Stampfer MJ, Pressel S, Rosner B, Taylor JO, Schneider KA, Hames CG. *Lancet* 1983; 1:130-134. (Paper 89A)
  53. **Effect of withdrawing diuretic therapy on blood pressure in mild hypertension.** Maland LJ, Lutz LJ, Castle CH. *Hypertension* 1983; 5:539-544. (Local Paper-Salt Lake City)
  54. **Training and certification of blood pressure observers.** Curb JD, Labarthe DR, Cooper SP, Cutter GR, Hawkins CM. *Hypertension* 1983; 5:610-614. (CCCT Paper)
  55. **A coordinating center in a clinical trial: The HDFP.** Curb JD, Ford CE, Hawkins CN, Smith EO, Zimbaldi N, Carter B, Cooper C. *Controlled Clinical Trials* 1983; 4:171-186. (CCCT Paper)
  56. **Serum cholesterol and cancer in the HDFP.** Morris DL, Borhani NO, Fitzsimmons E, Hardy RJ, Hawkins CM, Kraus J, Labarthe DR, Mastbaum L, Payne GH. *Cancer* 1983; 52:1754-1759. (Paper 49)
  57. **Hypertension Detection and Follow-up Program. Baseline characteristics of the enumerated, screened, and hypertensive participants.** Daugherty SA, Entwisle G, Curb JD, Polk BF, Taylor JO (Ed.). *Hypertension* 1983; 5(Suppl IV): IV-1 through IV-205. (Paper 3)
  58. **Effect of stepped care treatment on incidence of myocardial infarction and angina pectoris. Five-year findings of the HDFP.** HDFP Cooperative Group. *Hypertension* 1984; 6(Suppl):I-198 through I-206. (Final Paper 3)
  59. **Five-year findings of the HDFP: Mortality by race-sex and blood pressure level. A further analysis.** HDFP Cooperative Group. *J Comm Hlth* 1984; 9:314-327. (Final Paper 10)
  60. **The effect of antihypertensive drug treatment on mortality in the presence of resting electrocardiographic abnormalities at baseline: The HDFP experience.** HDFP Cooperative Group. *Circulation* 1984; 70:996-1003. (Final Paper 11)
  61. **Disability days associated with detection and treatment in a hypertension control program.** Polk BF, Harlan LC, Cooper SP, Stromer M, Ignatius J, Mull H, Blaszkowski TP. *Am J Epidemiol* 1984; 119:44-53. (Paper 29A)
  62. **Relation of serum vitamins A and E and carotenoids to the risk of cancer.** Willett WC, Polk BF, Underwood BA, Stampfer MJ, Pressel S, Rosner B, Taylor JO, Schneider KA, Hames CG, on behalf of the HDFP Cooperative Group. *N Engl J Med* 1984; 310:430-434. (Paper 89B)
  63. **Black-white comparison of indices of coronary heart disease and myocardial infarction in the stepped-care cohort of the HDFP.** Langford HG, Oberman A, Borhani NO, Entwisle G, Tung B. *American Heart Journal* 1984; 108:797-801. (Paper 58B)
  64. **The Hypertension Detection and Follow-up Program.** Langford HG. *NY St J Med* 1984; 84:287-288.
  65. **Termination of clinical trials: The BHAT and the HDFP experience.** Bell RL, Curb JD, Friedman LM, Payne GH. *Controlled Clinical Trials* 1985; 6:102-111.
  66. **Five-year findings of the HDFP: Prevention and reversal of left ventricular hypertrophy with antihypertensive drug therapy.** HDFP Cooperative Group. *Hypertension* 1985; 7:105-112. (Final Paper 4)
  67. **Mortality findings for stepped-care and referred-care participants in the HDFP, stratified by other risk factors.** HDFP Cooperative Group. *Prev Med* 1985; 14:312-335. (Final Paper 6)
  68. **Patient perceived side effects to antihypertensive drugs.** Curb JD, Borhani NO, Blaszkowski T, Zimbaldi N, Fotiu S, Williams W. *American Journal of Preventive Medicine* 1985; 1:36-40. (Paper 45B)
  69. **Apparent prevalence of curable hypertension in the HDFP.** Lewin A, Blaurock MD, Castle H, Entwisle G, Langford HG. *Archives of Internal Medicine* 1985; 145:424-427. (Paper 17)
  70. **Isolated systolic hypertension in 14 communities.** Curb JD, Borhani NO, Entwisle G, Tung B, Kass E, Schnaper H, Williams W, Berman R. *Am J Epidemiol* 1985; 121:362-370. (Paper 62B)
  71. **Detection and treatment of hypertension in older individuals.** Curb JD, Borhani NO, Schnaper H, Entwisle G, Kass E, Williams W, Berman R. *Am J Epidemiol* 1985; 121:371-376. (Paper 62A)
  72. **Ascertainment of vital status through the National Death Index and the Social Security Administration.** Curb JD, Ford CE, Pressel S, Palmer M, Babcock C, Hawkins CM. *Am J Epidemiol* 1985; 121:754-766. (CCCT Paper)
  73. **Cardiovascular morbidity and mortality in**

- the HDFP patients 50-69 years old at entry. Maxwell MH, Ford CE. *Journal of Cardiovascular Pharmacology* 1985; 7(Suppl 2):S5-S9. (Final Paper 9A)
74. **The relationship of weight and changes in blood pressure, serum uric acid, cholesterol and glucose in the treatment of hypertension.** Heyden S, Borhani NO, Tyroler HA, Schneider KA, Langford HG, Hames CG, Hutchinson R, Oberman A. *J Chron Dis* 1985;38:281-288. (Paper 14)
  75. **Long-term surveillance for adverse effects of antihypertensive drugs.** Curb JD, Borhani NO, Blaszkowski TP, Zimbaldi N, Fotiu S, Williams W. *JAMA* 1985; 253:3263-3268. (Paper 45A)
  76. **Comprehensive health care and noncardiovascular mortality: an unlikely explanation of the findings from the HDFP.** Heyden S, Schneider K, Fodor JG. *Circulation* 1985;72:692-696.
  77. **Systolic blood pressure as an independent predictor of mortality in the HDFP.** Abernethy J, Borhani NO, Hawkins CM, Crow R, Entwisle G, Jones JW, Maxwell MH, Langford HG, Pressel S. *Am J Prev Med* 1986; 2:123-132. (Paper 66)
  78. **The relationship between diuretics and serum cholesterol in HDFP participants.** Williams WR, Schneider KA, Borhani NO, Schnaper HW, Slotkoff LM, Ellefson RD. *American Journal of Preventive Medicine* 1986; 2:248-255. (Paper 36)
  79. **Effects of labeling and treatment of hypertension on perceived health.** Harlan LC, Polk BF, Cooper S, Blaszkowski TP, Ignatius-Smith J, Stromer M, Mull H. *Am J Prev Med* 1986; 2:256-261. (Paper 29B)
  80. **Results and implications of the Hypertension Detection and Follow-up Program.** E.H. Sonnenblick and M. Lesch editors with M.D. Blaufox as guest editor. *Progress in Cardiovascular Diseases* 1986; 29(Suppl 1):1-124.
  81. **Implications of the HDFP.** The HDFP Cooperative Group. *Progress in Cardiovascular Diseases* 1986;29:3-10. (Five-Year Monograph)
  82. **HDFP design, methods, and baseline characteristics and blood pressure response of the study participants.** Davis BR, Ford CE, Remington RD, Stamler R, Hawkins CM. *Progress Cardiovascular Diseases* 1986;29:11-28. (Five-Year Monograph)
  83. **All-cause mortality in the HDFP: Findings for the whole cohort and for persons with less severe hypertension, with and without other traits related to risk of mortality.** Langford HG, Stamler J, Wassertheil-Smoller S, Prineas RJ. *Progress Cardiovascular Diseases* 1986; 29:29-54. (Five-Year Monograph)
  84. **Incidence of coronary heart disease and left ventricular hypertrophy in the HDFP.** Borhani NO, Blaufox MD, Oberman A, Polk BF. *Prog Cardiovas Dis* 1986; 29:55-62. (Five-Year Monograph)
  85. **Cerebrovascular events in the HDFP.** Daugherty SA, Berman R, Entwisle G, Haerer AF. *Prog Cardiovas Dis* 1986; 29:63-72. (Five-Year Monograph)
  86. **Adverse effects of antihypertensive medications in the HDFP.** Curb JD, Maxwell MH, Schneider KA, Taylor JO, Shulman NB. *Prog Cardiovas Dis* 1986; 29:73-88. (Five-Year Monograph)
  87. **Mild hypertension: The question of treatment.** Labarthe DR. *Ann Rev Public Health* 1986; 7:193-215.
  88. **Caffeine consumption and mortality among 10,000 hypertensives.** Martin JB, Heyden S. *Café Cacao The* 1986; 30:281-288. (Paper 86A)
  89. **The association of postural changes in systolic blood pressure and mortality in persons with diastolic hypertension: The HDFP experience.** Davis BR, Langford HG, Blaufox MD, Curb JD, Polk BF, Shulman N. *Circulation* 1987; 75:340-346. (Paper 67)
  90. **Standardized physician preparation of death certificates.** Davis BR, Curb JD, Tung B, Hawkins CM, Ehrman S, Farmer J, Martin M. *Controlled Clinical Trials* 1987; 8:110-120. (CCCT Paper)
  91. **Is thiazide-produced uric acid elevation harmful? Analysis of data from the HDFP.** Langford HG, Blaufox MD, Borhani NO, Curb JD, Molteni A, Pressel S. *Arch Int Med* 1987; 147:645-649. (Paper 68)
  92. **Education level and five-year all cause mortality in the HDFP.** HDFP Cooperative Group. *Hypertension* 1987; 9:641-646. (Final Paper 7)
  93. **Failure to reduce cholesterol as explanation for the limited efficacy of antihypertensive treatment in the reduction of CHD. Evidence from the HDFP.** Schneider KA, Heyden S, Ford CE. *Nephron* 1987; 47(Suppl 1):104-107. (Paper 107A)
  94. **Recruitment in the HDFP.** Ford CE, Langford HG, Palmer M. *Controlled Clinical Trials* 1987; 8:54S-67S. (Paper 108)
  95. **Mortality at eight years for Hypertension Detection and Follow-up Program participants.** Langford HG. In *Mild Hypertension: From Drug Trials to Practice*. T. Strasser and D. Ganten, editors. Raven

- Press, NY, 1987; pp:45-52.  
(**PTS Final Paper 1A**)
96. **The relationship between degree of blood pressure reduction and mortality among hypertensives in the HDFP.** Cooper SP, Hardy RJ, Labarthe DR, Hawkins CM, Smith EO, Blaufox MD, Cooper C, Entwisle G, Maxwell MH, on behalf of the HDFP Cooperative Group. *American Journal of Epidemiology* 1988; 127:387-403. (**Paper 78**)
  97. **Persistence of reduction in blood pressure and mortality of participants in the Hypertension Detection and Follow-up Program.** HDFP Cooperative Group. *JAMA* 1988; 259:2113-2122. (**PTS Final Paper 1**)
  98. **Mortality patterns among hypertensives by reported level of caffeine consumption.** Martin JB, Annegers JF, Curb JD, Heyden S, Howson C, Lee ES, Lee M, on behalf of the HDFP Cooperative Group. *Prev Med* 1988; 17:310-320. (**Paper 86B**)
  99. **Coffee consumption and serum cholesterol in the HDFP.** Davis BR, Curb JD, Borhani NO, Prineas RJ, Molteni A, for the HDFP Cooperative Group. *American Journal of Epidemiology* 1988; 128:124-136. (**Paper 98**)
  100. **Mortality findings beyond five years in the Hypertension Detection and Follow-up Program.** Daugherty SA. *J Hypertension* 1988; 6(Suppl 4):S597-S601. (**PTS Final Paper 1B**)
  101. **Prognostic value of serum creatinine and the effect of treatment of hypertension on renal function. Results from the HDFP.** Shulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, Schneider KA. *Hypertension* 1989; 13(Suppl I):I-80—I-93. (**Paper 103**)
  102. **Why do lean hypertensives have higher mortality rates than other hypertensives? Findings from the Hypertension Detection and Follow-up Program.** Stamler R, Ford CE, Stamler J. *Hypertension* 1991; 17:553-564. (**Paper 116**)
  103. **Effect of thiazide-based therapy on serum alkaline phosphatase.** Langford HG, Curb JD, Pressel S, Schneider KA. *Journal of Human Hypertension* 1991; 5:333-338. (**Paper 35A**)
  104. **Serum cholesterol and coronary heart disease risk in female and older hypertensives: The experience under usual community care in the Hypertension Detection and Follow-up Program.** Tyroler HA, Ford CE. *Ann Epidemiol* 1992; 2:155-160. (**Paper 107B**)
  105. **At risk nephrons and the decline in renal function in response to treatment of hypertension.** Walker WG, Ford CE. *Transactions of the American Clinical and Climatological Association* 1995; 107:134-145. (**Paper 103B**)
  106. **The Hypertension Detection and Follow-up Program.** Davis BR, Ford CE. In *Clinical Trials in Hypertension*. HR Black, Editor. Marcel Dekker, NY, 2001; pp:27-60. (**Paper 109**)
- ### Letters
1. **Sodium excretion and sympathetic activity in relation to severity of hypertensive disease.** Hardy RJ, Cutter GR, Hawkins CM. Letter to the Editor. *Lancet* 1976; ii:471.
  2. **Treatment of hypertension.** Borhani NO. Letter to the Editor. *JAMA* 1978; 240:2541-2542.
  3. **Hypertension Detection and Follow-up Program.** HDFP Cooperative Group. Letter to the Editor. *JAMA* 1980; 244:1318.
  4. **Management of the mildly hypertensive patient.** Taylor JO, Polk BF. Letter to the Editor. *Hypertension* 1981; 3:629.
  5. **Should mild hypertension be treated?** Curb JD, Hawkins CM, Ford CE. Letter to the Editor. *N Engl J Med* 1982; 307:1522-1523.
  6. **Reduced stroke incidence in HDFP enhanced by strong support system.** Langford HG. Letter to the Editor. *Am Heart J* 1982; 103:1087-1088.
  7. **Treatment for mild hypertension.** Borhani NO, Langford HG, Hawkins CM, Curb JD. Letter to the Editor. *N Engl J Med* 1983; 308:524-525.
  8. **Treating mild hypertension.** Borhani NO, Langford HG. Letter to the Editor. *Ann Internal Med* 1984; 100:312-313.
  9. **Impact on interracial comparisons of inappropriate criteria for cardiac enlargement in blacks.** HDFP Editorial Review and Publications Committee. Letter to the Editor. *Hypertension* 1985; 7:1033.
  10. **"Goals of antihypertensive therapy: is there a point beyond which pressure reduction is dangerous?"** Cooper SP, Ford CE, Hardy RJ, Davis BR, Hawkins CM, Labarthe DR. Letter to the Editor. *American Journal of Hypertension* 1990; 3:733-734.
- ### Related Publications
- #### Phase I, Local Center Papers
1. **Medical News: NHLI sponsors program to identify hypertensives.** *JAMA* 1971; 217:888.
  2. **Diet treatment of obese hypertensives.** Heyden S, Tyroler HA, Hames G, Bartel A, Thompson JW, Krishan I, Rosenthal T. *Clin Sci & Molecular Med* 1973; 45:2095-2125.
  3. **Recent trends in hypertension control.** Ward

- GW, Johnson R. *Urban Health* 1976; June:38-39.
4. **Salt intake and the treatment of hypertension.** Langford HG, Watson RL, Thomas JG. *Am Heart J* 1977; 93:531-532.
  5. **Implications of findings in the HDFP.** Saunders E. *Urban Health* 1981; May:26-27, 40.
  6. **Should mild hypertension be treated?** Kass EH. *Trans Life Ins Med Dir Amer* 1981; 64:145-168. (Unauthorized publication)
  7. **Special clinics for hypertension — The role of the HDFP.** Kass EH. *Brit J Clin Pharmacology* 1982; 13:81-86.
  8. **Studies in hypertension: Implications for clinical medicine.** Stamler R. *Prev Med* 1983; 12:155-162.

### HDFP Presentations and Abstracts

The name of the presenter has been underlined when multiple authors are listed and only one made the presentation.

1. Remington RD, on behalf of the HDFP. **The Hypertension Detection and Follow-up Program.** (Presented at the INVITED SESSION AT LES COLLEQUES DE L'INSTITUT NATIONAL DE LA SANTE ET DE LA RACHERCHE MEDICALE. France, September 1973.)
2. Langford HG, on behalf of the HDFP. **The Hypertension Detection and Follow-up Program.** (Presented at the INVITED SESSION AT THE INTERNATIONAL HYPERTENSION SYMPOSIUM. Chicago, Illinois, September 1974.)
3. Oberman A, on behalf of the HDFP. **Results of two-stage screen in the HDFP.** (Presented at AHA 47TH SCIENTIFIC SESSIONS. Dallas, Texas, November 1974.) [Abstract: \*Circulation\* 1974; 50\(Suppl III\):III-10.](#)
4. Blaurox MD, on behalf of the HDFP. **Normalization of blood pressure in Stepped Care participants of the HDFP.** (Presented at AHA 47th Scientific Sessions, Dallas, Texas, November 1974.) [Abstract: \*Circulation\* 1974; 50\(Suppl III\):III-148.](#)
5. Langford HG, on behalf of the HDFP. **The Hypertension Detection and Follow-up Program.** (Presented at an INVITED SESSION OF THE WORLD HEALTH ORGANIZATION MEETING. Madrid, Spain, March 1975.)
6. Wassertheil-Smoller S, on behalf of the HDFP. **Improvement in current community control of hypertension.** (Presented at 48TH SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION. Anaheim, California, November 1975.) [Abstract: \*Circulation\* 1975; 52\(Suppl II\):II-54.](#)
7. McDill MS, Heymsfield S, Kraus JF, Lee ES, Stamler R, Watson R. **The relationship of socioeconomic status and blood pressure.** (Presented at the 103RD AMERICAN PUBLIC HEALTH ASSOCIATION ANNUAL MEETING. Chicago, Illinois, November 1975.) [Abstract: \*Program & Abstracts of 103rd Annual Meeting of APHA\* 1975; pp.138.](#)
8. Taylor JO, on behalf of the HDFP. **The Hypertension Detection and Follow-up Program: A progress report.** (Presented at the INVITED SESSION AT THE COUNCIL ON HIGH BLOOD PRESSURE RESEARCH SYMPOSIUM: THE PRELIMINARY RESULTS IN PATIENTS WITH MILD HYPERTENSION. Cleveland, Ohio, October 1976.)
9. Hemsfield S, Kraus J, Lee ES, McDill M, Stamler R, Watson R, on behalf of the HDFP. **Multivariate analysis of elevated blood pressure with race, SES, and their correlates.** (Presented at the 16TH ANNUAL CONFERENCE ON CARDIOVASCULAR DISEASE EPIDEMIOLOGY. New Orleans, Louisiana, February 1976.) [Abstract: \*CVD Epidemiol Newsletter\* 1976; 20:53.](#)
10. Cutter GR, on behalf of the HDFP. **Laboratory quality control in the HDFP.** (Presented at a special session of the AMERICAN PUBLIC HEALTH ASSOCIATION ANNUAL MEETING: STATISTICAL ASPECTS OF LABORATORY QUALITY CONTROL PROCEDURES IN COLLABORATIVE CLINICAL TRIALS. Miami, Florida, October 1976.)
11. Borhani NO, on behalf of the HDFP. **The Hypertension Detection and Follow-up Program.** (Presented at the 5TH HAHNEMAN INTERNATIONAL SYMPOSIUM ON HYPERTENSION DETERMINANTS, COMPLICATIONS AND INTERVENTION. Puerto Rico, January 1977.)
12. Polk BF, on behalf of the HDFP. **Mild hypertensives in the HDFP.** (Presented at the NEW YORK ACADEMY OF SCIENCES MEETING. New York, February 1977.)
13. Payne GH, on behalf of the HDFP. **The Hypertension Detection and Follow-up Program.** (Presented at the AMERICAN COLLEGE OF CARDIOLOGY SYMPOSIUM ON CLINICAL TRIALS. Las Vegas, Nevada, March 1977.)
14. Heyden S, on behalf of the HDFP. **The relationship of weight change to blood pressure and its correlates.** (Presented at the 17TH ANNUAL CONFERENCE ON CARDIOVASCULAR DISEASE EPIDEMIOLOGY. San Diego, California, March 1977.) [Abstract: \*CVD Epidemiology Newsletter\* 1977; 22:38.](#)
15. Prineas R, on behalf of the HDFP. **Sex and race differences in end-organ damage among 10,940 hypertensives.** (Presented at AMERICAN COLLEGE OF CARDIOLOGY SCIENTIFIC SESSION. Anaheim, California, March 1978.) [Abstract: \*Am J Cardiol\* 1978; 41:402.](#)
16. The HDFP Cooperative Group. **Patient participation in antihypertensive follow-up and treatment program. The HDFP.** [Abstract: \*Prev Med\* 1978; 7\(1\):92.](#)
17. Borhani NO, on behalf of the HDFP. **Demographic features of interviewers and their effect on blood pressure.** (Presented at the NATIONAL CONFERENCE ON HIGH BLOOD PRESSURE CONTROL in Los Angeles, California, April 1978.) [Abstract: \*Prev Med\* 1978; 7\(1\):91.](#)
18. Sigourney L, on behalf of the HDFP. **Blood pressure studies in 14 communities: A two-stage screen.** (Poster presentation at NATIONAL CONFERENCE ON HIGH BLOOD PRESSURE CONTROL. Los Angeles, California, April 1978.) [Abstract: \*Prev Med\* 1978; 7:90.](#)
19. Polk BF, on behalf of the HDFP. **Therapeutic control of blood pressure after one year in the HDFP.** (Presented at the NATIONAL CONFERENCE ON HIGH BLOOD PRESSURE

- CONTROL., Los Angeles, California, April 1978.)  
**Abstract:** [Prev Med 1978; 7:92.](#)
20. Smith EO. **Life table analysis of time until drop-out in the HDFP.** (Presented at the 4TH ANNUAL MEETING OF PERSONNEL INVOLVED IN COORDINATING COLLABORATIVE CLINICAL TRIALS. Chapel Hill, North Carolina, May 1977.)
  21. Ford CE. **Monitoring clinical trial study data acquisition by means of an interactive information management system.** (Presented at the 4TH ANNUAL MEETING OF PERSONNEL INVOLVED IN COORDINATING COLLABORATIVE CLINICAL TRIALS. Chapel Hill, North Carolina, May 1977.)
  22. Langford HG, on behalf of the HDFP. **The Hypertension Detection and Follow-up Program.** (Presented at a WHO INTERNATIONAL SYMPOSIUM ON PROPHYLACTIC APPROACH TO HYPERTENSIVE DISEASE. Izumo, Japan, September 1978.)
  23. Wassertheil-Smoller S, on behalf of the HDFP. **Recent status of community detection, treatment, and control of hypertension.** (Presented at the APHA ANNUAL MEETING. Los Angeles, California, October 1978.) **Abstract:** [Program and Abstracts of 106th Annual Meeting of APHA 1978, p.126.](#)
  24. HDFP Cooperative Group. **Description and comparison of the role of medical therapists within and between clinical centers of the HDFP.** **Abstract:** [Prev Med 1979; 8:175.](#)
  25. Levy RI, Payne GH, Langford HG, Stamler J. PRESS CONFERENCE: **The Five-Year Findings of the Hypertension Detection and Follow-up Program—A Multi-Year Clinical Trial.** (Presented in Bethesda, Maryland, November 1979.)
  26. Sigourney L, on behalf of the HDFP. **Disability days associated with detection and treatment in the HDFP.** (Presented at the 52ND SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION. Anaheim, California, November 1979.) **Abstract:** [Circulation 1979; 60\(Suppl II\):II-67.](#)
  27. Blaufox MD, Langford HG, Ford CE, on behalf of the HDFP. **End-organ damage in hypertension and medication requirements for control of blood pressure.** (Presented at the 52ND SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION. Anaheim, California, November 1979.) **Abstract:** [Circulation 1979; 60\(Suppl II\):II-68.](#)
  28. Langford HG, Borhani NO, Stamler J, Gifford RW, Levy RI. **Findings of the HDFP.** (Panel presentation at the AMERICAN COLLEGE OF CARDIOLOGY CORE CURRICULUM SESSIONS: CONTEMPORARY PROBLEMS IN HYPERTENSION. Houston, Texas, March 1980.)
  29. Maxwell M, on behalf of the HDFP. **Final results of the HDFP.** (Presented at 7TH SCIENTIFIC MEETING OF THE INTERNATIONAL SOCIETY OF HYPERTENSION. New Orleans, Louisiana, May 1980.)
  30. Poizner S, on behalf of the HDFP. **Disability days associated with detection and treatment in the HDFP.** (Presented at the NATIONAL CONFERENCE ON HIGH BLOOD PRESSURE CONTROL. Houston, Texas, May 1980.) **Abstract:** [Prev Med 1980; 9:425.](#)
  31. Molteni A, on behalf of the HDFP. **Serum sodium in patients in the HDFP: A preliminary report of the first four years of the study.** (Presented at the 59TH MEETING OF THE ASSOCIATION OF CLINICAL SCIENTIST. Boston, Massachusetts, May 1980.) **Abstract:** [Ann Clinical & Laboratory Sci 1980; 10:450.](#)
  32. Borhani NO, Langford HG, and non-HDFP Investigators. (PANEL PRESENTATION IN A SATELLITE PROGRAM: **Implications of the Australian Study and HDFP.** September 1980.)
  33. Apostolides AY, Cutter G, Daugherty S, Detels R, Kraus J, Smoller S, Ware J, on behalf of the HDFP. **Three-year incidence of hypertension in 13 U.S. communities.** (Poster presentation at the 53RD SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION. Miami, Florida, November 1980.) **Abstract:** [Circulation 1980; 62\(Suppl III\):III-305.](#)
  34. Curb JD, Borhani NO, Williams W, Johnson J, Zimbaldi N, Blaszkowski T, Fotiu S, on behalf of the HDFP. **Patient reported side effects to antihypertensive medications.** (Poster presentation at the 53RD SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION. Miami, Florida, November 1980.) **Abstract:** [Circulation 1980; 62\(Suppl III\):III-306.](#)
  35. Curb JD, Schnaper H, Williams W, Berman R, Entwisle G, Kass E, on behalf of the HDFP. **Hypertension in the elderly.** (Presented at the 53RD SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION. Miami, Florida, November 1980.) **Abstract:** [Circulation 1980; 62\(Suppl III\):III-223.](#)
  36. Langford HG, Daugherty SA, Castle CH, Levy RI. **Findings of the HDFP.** (Panel for the AHA Arena Presentation at the 53RD SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION. Miami, Florida, November 1980.)
  37. Molteni A, on behalf of the HDFP. **The effect of hypertension on serum indicators of renal function.** (Presented at the ASSOCIATION OF CLINICAL SCIENTIST MEETING. Chicago, Illinois, November 1980.)
  38. Curb JD, Schnaper H, Berman R, Entwisle G, Kass E, Williams W, on behalf of the HDFP. **Hypertension in the elderly: The HDFP screening experience.** **Abstract:** [CVD Epidemiology Newsletter 1981; 30:37.](#)



39. Curb JD, Hardy RJ, Labarthe D, Borhani NO, Taylor J, on behalf of the HDFP. **Reserpine and breast cancer in hypertensives.** (Presented at the 21ST ANNUAL CONFERENCE ON CARDIOVASCULAR DISEASE EPIDEMIOLOGY. Washington, D.C., March 1981.) [Abstract: CVD Epidemiology Newsletter 1981; 30:32.](#)
40. Borhani NO, on behalf of the HDFP. **Reduction in stroke incidence among persons with high blood pressure.** (Presented at AMERICAN EPIDEMIOLOGICAL SOCIETY. Chicago, Illinois, April 1981.)
41. Curb JD, Langford H, Harrist R, Molteni A, Mastbaum L, Tyroler H, Williams W, on behalf of the HDFP. **Effect of age and thiazide diuretics on alkaline phosphatase.** [Abstract: Clinical Research 1981; 29:537A.](#)
42. Labarthe D. **The relationship between serum cholesterol and cancer incidence in the population of the HDFP.** (Presented at the WORKSHOP ON CHOLESTEROL AND NONCARDIOVASCULAR DISEASE MORTALITY. Bethesda, Maryland, May 1981.)
43. Curb JD, Hawkins CM, Smith EO, Zimbaldi N, Ford CE, Carter B, Cooper C. **The coordinating center in a clinical trial.** (Presented at the 2ND ANNUAL MEETING OF THE SOCIETY FOR CLINICAL TRIALS. San Francisco, California, May 1981. [Abstract: Controlled Clinical Trials 1981; 2:83.](#)
44. Curb JD, Labarthe D, Cutter G, Poizner S, Hawkins CM. **Training and certification of blood pressure observers in a clinical trial.** (Presented at the 2ND ANNUAL MEETING OF THE SOCIETY FOR CLINICAL TRIALS. San Francisco, California, May 1981.) [Abstract: Controlled Clinical Trials 1981; 2:87.](#)
45. Curb JD, on behalf of the HDFP. **Reduction in stroke incidence among persons with high blood pressure.** (Presented at 14TH MEETING OF THE SOCIETY FOR EPIDEMIOLOGIC RESEARCH. Snowbird, Utah, June 1981.) [Abstract: Am J Epidemiol 1981; 114:430.](#)
46. Borhani NO, on behalf of the HDFP. **Mortality reduction among persons with "mild" hypertension.** (Presented at Plenary Session of the 14TH MEETING OF THE SOCIETY FOR EPIDEMIOLOGIC RESEARCH. Snowbird, Utah, June 1981.) [Abstract: Am J Epidemiol 1981; 114:444.](#)
47. Smith EO, Curb JD, Hardy RJ, Hawkins CM, Tyroler HA, on behalf of the HDFP. **Factors associated with compliance to antihypertensive medications.** (Presented at the 14TH MEETING OF THE SOCIETY FOR EPIDEMIOLOGIC RESEARCH. Snowbird, Utah, June 1981.) [Abstract: Am J Epidemiol 1981; 114:418.](#)
48. Blafox MD, on behalf of the HDFP. **Regression of left ventricular hypertrophy with hypertensive therapy.** (Presented at 54TH SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION. Dallas, Texas, November 1981.) [Abstract: Circulation 1981; 64\(Suppl IV\):IV-322.](#)
49. Langford HG, Curb JD, Blafox D, Borhani NO, Chakrin A, on behalf of the HDFP. **Thiazide produced uric acid elevations do not cause renal damage.** (Presented at the SOUTHERN SOCIETY FOR CLINICAL INVESTIGATION MEETING. New Orleans, Louisiana, January 1982.) [Abstract: Clinical Research 1981; 29:865A.](#)
50. Langford HG, on behalf of the HDFP. **Further findings of HDFP.** (Presented at INTERNATIONAL SOCIETY OF HYPERTENSION MEETING. Mexico City, February 1982.)
51. Langford HG, on behalf of the HDFP. **Beneficial effect of the HDFP Stepped Care regimen on indices of coronary artery and myocardial disease.** (Presented at the 22ND ANNUAL CONFERENCE ON CARDIOVASCULAR DISEASE EPIDEMIOLOGY. San Antonio, Texas, March 1982.) [Abstract: CVD Epidemiology Newsletter 1982; 32:xx.](#)
52. Polk BF, on behalf of the HDFP. **Effect of antihypertensive medication on left ventricular hypertrophy.** (Presented at the 22ND ANNUAL CONFERENCE ON CARDIOVASCULAR DISEASE EPIDEMIOLOGY. San Antonio, Texas, March 1982.) [Abstract: CVD Epidemiology Newsletter 1982; 32:xx.](#)
53. Daugherty SA, on behalf of the HDFP. **Reduction in stroke incidence among persons with high blood pressure.** (Presented at the 22ND ANNUAL CONFERENCE ON CARDIOVASCULAR DISEASE EPIDEMIOLOGY. San Antonio, Texas, March 1982.) [Abstract: CVD Epidemiology Newsletter 1982; 32:xx.](#)
54. Taylor JO, on behalf of the HDFP. **Mortality in the HDFP by race, sex, and blood pressure level—a further analysis.** (Presented at the 22ND ANNUAL CONFERENCE ON CARDIOVASCULAR DISEASE EPIDEMIOLOGY. San Antonio, Texas, March 1982.) [Abstract: CVD Epidemiology Newsletter 1982; 32:xx.](#)
55. Borhani NO, on behalf of the HDFP. **Mortality reduction among persons with "mild" hypertension.** (Presented at the 22ND ANNUAL CONFERENCE ON CARDIOVASCULAR DISEASE EPIDEMIOLOGY. San Antonio, Texas, March 1982.) [Abstract: CVD Epidemiology Newsletter 1982; 32:xx.](#)
56. Langford HG, on behalf of the HDFP. **Prognostic importance and effect of Stepped Care regimen on indices of coronary artery and myocardial disease.** (Presented at the SOUTHERN SOCIETY FOR CLINICAL INVESTIGATION MEETING. New Orleans, Louisiana, January 1982.) [Abstract: Clinical Research 1982; 30:547A.](#)
57. Curb JD, Langford HG, Blafox D, Borhani NO, Chakrin A, on behalf of the HDFP. **Thiazide**

- produced uric acid elevations do not cause renal damage. *Abstract: Clinical Research 1982; 30:509A.*
58. Borhani NO, on behalf of the HDFP. **Beneficial effect of the HDFP Stepped Care regimen on indices of coronary artery and myocardial disease.** (Presented at the AMERICAN COLLEGE OF CARDIOLOGY SCIENTIFIC SESSION. Atlanta, Georgia, April 1982.) *Abstract: Am J Cardiol 1982; 49:912.*
  59. Taylor JO, on behalf of the HDFP. **The Hypertension Detection and Follow-up Program: a systematic approach that works.** Presented at ASSOCIATION OF TEACHERS OF PREVENTIVE MEDICINE. Bethesda Maryland, April 1982.
  60. Curb JD, Babcock C, Pressel S, Tung B, Hawkins CM. **Nosological coding of cause of death in a clinical trial.** (Presented at the 3RD ANNUAL MEETING OF THE SOCIETY FOR CLINICAL TRIALS. Pittsburg, Pennsylvania, May 1982.) *Abstract: Controlled Clinical Trials 1982; 3:141.*
  61. Polk BF, on behalf of the HDFP. **Effect of antihypertensive medication on left ventricular hypertrophy.** (Presented at 15TH MEETING OF THE SOCIETY FOR EPIDEMIOLOGIC RESEARCH. Cincinnati, Ohio, June 1982.) *Abstract: AM J Epidemiol 1982; 116:579.*
  62. Taylor JO, on behalf of the HDFP. **Mortality in the HDFP by race, sex, and blood pressure level—a further analysis.** (Presented at 15TH MEETING OF THE SOCIETY FOR EPIDEMIOLOGIC RESEARCH. Cincinnati, Ohio, June 1982.) *Abstract: AM J Epidemiol 1982; 116:578.*
  63. Borhani NO. **Beneficial effect of the HDFP Stepped Care regimen on indices of coronary artery and myocardial disease.** (Presented at the 15TH MEETING OF THE SOCIETY FOR EPIDEMIOLOGIC RESEARCH. Cincinnati, Ohio, June 1982.) *Abstract: AM J Epidemiol 1982; 116:578.*
  64. Curb JD, Schnaper H, Williams W, Entwisle G, Kass E, Borhani NO, on behalf of the HDFP. **Detection and treatment of hypertension in the elderly.** (Presented at the 15TH MEETING OF THE SOCIETY FOR EPIDEMIOLOGIC RESEARCH. Cincinnati, Ohio, June 1982.) *Abstract: AM J Epidemiol 1982; 116:578.*
  65. Stamler J. **Five-year morbidity and mortality in the HDFP.** (Presented at IX WORLD CONGRESS OF CARDIOLOGY. Moscow, USSR, June 1982.)
  66. Tyroler HA. **Race, education, and five-year mortality in HDFP stratum I Referred Care males.** (Presented in an Invited Session at the 3RD WHO/ISH CONFERENCE ON MILD HYPERTENSION: RECENT ADVANCES. Geneva, Switzerland, September 1982.)
  67. Langford HG. **Further analyses of the HDFP.** (Presented in an Invited Session at WHO MEETING. Geneva, Switzerland, September 1982.)
  68. Berman R. **Mortality reduction among persons with "mild" hypertension.** (Presented at 5TH SCIENTIFIC MEETING OF THE WORKING GROUP ON EPIDEMIOLOGY AND PREVENTION OF THE EUROPEAN SOCIETY OF CARDIOLOGY. Barcelona, Spain, September 1982.)
  69. Blaurock MD. **Reduction in hypertension mortality through Stepped Care in the HDFP, and reduction in cardiovascular complications of hypertension in the HDFP.** (Presented at the INTERNATIONAL SYMPOSIUM ON HYPERTENSION CONTROL IN THE COMMUNITY. Tel Aviv, Israel, October 1982.)
  70. HDFP Investigators. CONFERENCE ON THE IMPLICATIONS OF THE HYPERTENSION DETECTION AND FOLLOW-UP PROGRAM. Bethesda, Maryland, November 1982.
  71. Curb JD, Borhani NO, Blaszkowski T, Fotiu S, Zimbaldi N, on behalf of the HDFP. **Adverse reactions to antihypertensive drugs in the HDFP.** (Presented at the 55TH SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION. Dallas, Texas, November 1982.) *Abstract: Circulation 1982; 66(Suppl II):II-328.*
  72. Daugherty SA, Curb JD, Pressel S, Taylor JO, Apostolides A, Newman B, Detels R, on behalf of the HDFP. **The relationship of blood pressure to 5-year mortality in a community-based population.** (Presented at the 55TH SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION. Dallas, Texas, November 1982.) *Abstract: Circulation 1982; 66(Suppl II):II-236.*
  73. Oberman A, Entwisle G, Langford H, Borhani N, Tung B, on behalf of the HDFP. **Assessing racial differences in angina pectoris among hypertensives.** (Presented at the 55TH SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION. Dallas, Texas, November 1982.) *Abstract: Circulation 1982; 66(Suppl II):II-314.*
  74. Hardy RJ, Hawkins CM, on behalf of the HDFP. **The impact of selected indices of antihypertensive treatment on all-cause mortality.** (Presented at the 55TH SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION. Dallas, Texas, November 1982.) *Abstract: Circulation 1982; 66(Suppl II):II-328.*
  75. Langford HG, on behalf of the HDFP. **Blood pressure and CHD indices and mortality in HDFP.** (Presented in an Invited Session at the 23RD ANNUAL CONFERENCE ON CARDIOVASCULAR DISEASE EPIDEMIOLOGY: SYMPOSIUM ON CORONARY HEART DISEASE IN BLACK POPULATIONS. San Diego, California, March 1983.)
  76. Hardy RJ, Hawkins CM, on behalf of the HDFP. **The impact of selected indices of antihypertensive treatment on all-cause**

- mortality.** (Presented at the 23RD ANNUAL CONFERENCE ON CARDIOVASCULAR DISEASE EPIDEMIOLOGY. San Diego, California, March 1983.) **Abstract:** [CVD Epidemiology Newsletter 1983; 33:48.](#)
77. Lewin A, Blaurox MD, Castle CH, Entwisle G, Langford HG, on behalf of the HDFP. **The occurrence of renal and reversible hypertension in a community-based hypertensive population.** (Presented at the AMERICAN COLLEGE OF CARDIOLOGY SCIENTIFIC MEETING. New Orleans, Louisiana, March 1983.) **Abstract:** [J Am College Cardiol 1983; 1\(Part 2\):622.](#)
78. Williams WR, Borhani NO, Schnaper HW, Schneider KA, Slotkoff L, on behalf of the HDFP. **The relationship between diuretics and serum cholesterol in HDFP participants.** (Presented at the AMERICAN COLLEGE OF CARDIOLOGY SCIENTIFIC MEETING. New Orleans, Louisiana, March 1983.) **Abstract:** [J Am College Cardiol 1983; 1\(Part 2\):623.](#)
79. Schneider KA, on behalf of the HDFP. **Mortality reduction among persons with "mild" hypertension.** (Presented at NATIONAL CONFERENCE ON HIGH BLOOD PRESSURE CONTROL. Washington D.C., April 1983.)
80. Williams WR, Borhani NO, Schnaper HW, Schneider KA, Slotkoff L, on behalf of the HDFP. **The relationship between diuretics and serum cholesterol in HDFP participants.** (Presented at NATIONAL CONFERENCE ON HIGH BLOOD PRESSURE CONTROL. Washington D.C., April 1983.)
81. Curb JD, Hardy RJ, Hawkins CM, on behalf of the HDFP. **The impact of selected indices of antihypertensive treatment on all-cause mortality.** (Presented at NATIONAL CONFERENCE ON HIGH BLOOD PRESSURE CONTROL. Washington D.C., April 1983.)
82. Curb JD, Borhani NO, Blaszkowski T, Fotiu S, Zimbaldi N, on behalf of the HDFP. **Adverse reactions to antihypertensive drugs in the HDFP.** (Presented at NATIONAL CONFERENCE ON HIGH BLOOD PRESSURE CONTROL. Washington D.C., April 1983.)
83. Schneider KA, on behalf of the HDFP. **The relationship between diuretics and serum cholesterol: The HDFP experience.** (Presented at the WORKSHOP ON THE ROLE OF DIETARY MANAGEMENT IN THE REDUCTION OR REVERSAL OF BLOOD LIPID ELEVATIONS INDUCED BY ANTIHYPERTENSIVE MEDICATIONS. Bethesda, Maryland, April 1983.)
84. Curb JD, Palmer M, Pressel S, Ford CE, Zimbaldi N, Babcock C, Jennings P, Hawkins CM. **Ascertaining living status through the National Death Index and the Social Security Administration.** (Presented at the 4TH ANNUAL MEETING OF THE SOCIETY FOR CLINICAL TRIALS. St. Louis, Missouri, May 1983.) **Abstract:** [Controlled Clinical Trials 1983; 4:154.](#)
85. Abernethy JD. **Extraction of aging effects from censored survival data.** (Presented at the 4TH ANNUAL MEETING OF THE SOCIETY FOR CLINICAL TRIALS. St. Louis, Missouri, May 1983.) **Abstract:** [Controlled Clinical Trials 1983; 4:161.](#)
86. Daugherty SA, Apostolides A, Borhani N, Curb J, Detels R, Newman B, Pressel S, Taylor J, Tucker W, on behalf of the HDFP. **The relationship of screening blood pressure to subsequent 8-year mortality in the HDFP.** (Presented at the 16TH MEETING OF THE SOCIETY FOR EPIDEMIOLOGIC RESEARCH. Winnepeg, Canada, June 1983.) **Abstract:** [AM J Epidemiol 1983; 118:442.](#)
87. Polk BF. **Evidence for an association between first birth order and hypertension.** (Presented at the 16TH MEETING OF THE SOCIETY FOR EPIDEMIOLOGIC RESEARCH. Winnepeg, Canada, June 1983.) **Abstract:** [Am J Epidemiol 1983; 118:413.](#)
88. Ellefson RD, on behalf of the HDFP. **The relationship between diuretics and serum cholesterol in HDFP participants.** (Presented at the XIII WORLD CONGRESS OF THE INTERNATIONAL UNION OF ANGIOLOGY. Rochester, Minnesota, September 1983.)
89. Taylor JO, on behalf of the HDFP. **Prevention and reversal of left ventricular hypertrophy and cardiomegaly with antihypertensive drug therapy.** (Presented at the EASTERN SECTION MEETING OF THE AMERICAN FEDERATION FOR CLINICAL RESEARCH. Cambridge, Massachusetts, October 1983.)
90. Taylor JO, on behalf of the HDFP. **Findings of the HDFP.** (Presented at the THIRD ASIAN SYMPOSIUM ON HYPERTENSION. Denpasar-Bali, Indonesia, November 1983.)
91. Curb JD, Borhani NO, Entwisle G, Kass EH, Schanper HW, Williams WR, Tung B, on behalf of the HDFP. **Isolated systolic hypertension in 14 communities.** (Presented at the 56TH SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION. Anaheim, California, November 1983.) **Abstract:** [Circulation 1983; 68\(Suppl III\):III-125.](#)
92. Heyden S, Tyroler HA, Schneider KA, Borhani NO, Langford HG, Hames CG, Hutchinson R, Oberman A, on behalf of the HDFP. **Weight change and changes in blood pressure, serum uric acid, cholesterol, and glucose in the treatment of hypertension.** (Presented at the 56TH SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION. Anaheim, California, November 1983.) **Abstract:** [Circulation 1983; 68\(Suppl III\):III-91.](#)
93. Borhani NO, on behalf of the HDFP. **Prevention and reversal of left ventricular hypertrophy and cardiomegaly with**

- antihypertensive drug therapy.** (Presented at the WESTERN SECTION MEETING OF THE AMERICAN FEDERATION FOR CLINICAL RESEARCH. Carmel, California, February, 1984.)
94. Borhani NO, on behalf of the HDFP. **Effect of Stepped Care treatment on the incidence of myocardial infarction and angina pectoris.** (Presented at the WESTERN SECTION MEETING OF THE AMERICAN FEDERATION FOR CLINICAL RESEARCH. Carmel, California, February, 1984.)
  95. Maxwell MH, Ford CE, on behalf of the HDFP. **Cardiovascular morbidity and mortality in HDFP patients 50-69 years old at entry.** (Presented at a SATELLITE SYMPOSIUM ON CARDIOVASCULAR MORBIDITY AND LARGE ARTERIES IN HYPERTENSION. Paris, France, June 1984.)
  96. Stamler J, on behalf of the HDFP. **Mortality findings for Stepped Care and Referred Care participants in the HDFP, stratified by other risk factors.** (Presented at the 57TH SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION. Miami Beach, Florida, November 1984.) [Abstract: \*Circulation\* 1984; 70\(Suppl III\):??.](#)
  97. Langford HG, Ford CE, Blaufox MD, on behalf of the HDFP. **Is hypertension worse in blacks? Comparison of creatinine levels at equal blood pressures; effect of potassium.** (Presented at the 17TH ANNUAL MEETING OF THE AMERICAN SOCIETY OF NEPHROLOGY. New Orleans, Louisiana, January 1985.)
  98. Stamler R, on behalf of the HDFP. **Education level, hypertension treatment, and 5-year mortality in the HDFP.** (Presented at the 25TH ANNUAL CONFERENCE ON CARDIOVASCULAR DISEASE EPIDEMIOLOGY. Tucson, Arizona, March 1985.) [Abstract: \*Circulation\* 1985; 71:413A.](#)
  99. Davis BR, Langford HG, Blaufox MD, Polk BF, Shulman NB, Curb JD, on behalf of the HDFP. **Postural hypotension in a hypertensive population.** (Presented at the 25TH ANNUAL CONFERENCE ON CARDIOVASCULAR DISEASE EPIDEMIOLOGY. Tucson, Arizona, March 1985.) [Abstract: \*Circulation\* 1985; 71:415A.](#)
  100. Daugherty SA, Curb JD, Ford CE, Hawkins CM, Langford HG, Pressel S, Taylor JO, on behalf of the HDFP. **Eight-year follow-up of participants in the HDFP: persistence of reduction in blood pressure and mortality in a treated hypertension population.** (Presented at the 25TH ANNUAL CONFERENCE ON CARDIOVASCULAR DISEASE EPIDEMIOLOGY. Tucson, Arizona, March 1985.) [Abstract: \*Circulation\* 1985; 71:417A.](#)
  101. Davis BR, Curb JD, Borhani NO, Prineas R, Molteni A. **Coffee and serum cholesterol in the HDFP.** (Poster presentation at the 25TH ANNUAL CONFERENCE ON CARDIOVASCULAR DISEASE EPIDEMIOLOGY. Tucson, Arizona, March 1985.) [Abstract: \*CVD Epidemiology Newsletter\* 1985; 37:48.](#)
  102. Curb JD, Davis BR, Tung B. **Standardized physician preparation of death certificates.** (Presented at the 6TH ANNUAL MEETING OF THE SOCIETY FOR CLINICAL TRIALS. New Orleans, Louisiana, May 1985.) [Abstract: \*Controlled Clinical Trials\* 1985; 6:237.](#)
  103. Cooper SP, on behalf of the HDFP. **The relationship between degree of blood pressure reduction and mortality among hypertensives in the HDFP.** Presented at the 58TH SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION. Washington, D.C., November 1985. [Abstract: \*Circulation\* 1985; 72\(Suppl III\):III-186.](#)
  104. Davis BR, Langford HG, Oberman A, Shulman N, Wassertheil-Smoller S. **Isolated diastolic hypertension in the HDFP.** (Presented at the 26TH ANNUAL CONFERENCE ON CARDIOVASCULAR DISEASE EPIDEMIOLOGY. San Francisco, California, March 1986.) [Abstract: \*CVD Epidemiology Newsletter\* 1986; 39:19.](#)
  105. Ford CE, Langford HG, Palmer MJ. **Recruitment in the Hypertension Detection and Follow-up Program.** Presented at the NHLBI WORKSHOP ON THE RECRUITMENT EXPERIENCE IN NHLBI-SPONSORED CLINICAL TRIALS. Bethesda, Maryland, April 1986. [Abstract: \*Controlled Clinical Trials\* 1987; 8\(Suppl\):??.](#)
  106. Ford CE, on behalf of the HDFP. **Eight-year follow-up of participants in the HDFP: persistence of reduction in blood pressure and mortality in a treated hypertension population.** (Presented at the 52ND ANNUAL SCIENTIFIC ASSEMBLY OF THE AMERICAN COLLEGE OF CHEST PHYSICIANS. San Francisco, California, September 1986.) [Abstract: \*Chest\* 1986; 89:496S \(abstract\).](#)
  107. Schneider KA, Heyden S, Ford CE. **Failure to reduce cholesterol as explanation for limited efficacy of antihypertensive treatment in the reduction of CHD. Evidence from the HDFP.** (Presented at a Satellite Symposium of the 11TH CONGRESS OF THE INTERNATIONAL SOCIETY OF HYPERTENSION, Titisee, Federal Republic of Germany, September 1986.) Proceedings published in [Nephron 1987; 47\(Suppl I\).](#)
  108. Borhani NO, on behalf of the HDFP. **Eight-year follow-up of participants in the HDFP: persistence of reduction in blood pressure and mortality in a treated hypertension population.** (Presented at the 11TH CONGRESS OF THE INTERNATIONAL SOCIETY OF HYPERTENSION. Heidelberg, Federal Republic of Germany, September 1986.)
  109. Schneider KA, Ford CE, Davis BR, Heyden S, Tyroler HA. **Cholesterol and coronary heart disease in HDFP hypertensive participants.** (Presented at the 27TH ANNUAL CONFERENCE ON

- CARDIOVASCULAR DISEASE EPIDEMIOLOGY.  
Charleston, South Carolina, March 1987.)  
**Abstract:** *CVD Epidemiology Newsletter* 1987; 41:??
110. Ford CE, Shulman NB, on behalf of the HDFP. **Prevalence, incidence, prognostic value, and treatment implications of renal disease in a hypertensive population.** (Presented at the NHLBI WORKSHOP ON ANTIHYPERTENSIVE DRUG TREATMENT: THE BENEFITS, COSTS, AND CHOICES. Bethesda, Maryland, June 1987.) Proceedings published in a Supplement to *Hypertension* 1989; 13(Suppl 1):I-80—I-93.
111. Daugherty SA, on behalf of the HDFP. **Mortality findings beyond five years in the HDFP.** (Presented at the 12TH SCIENTIFIC MEETING OF THE INTERNATIONAL SOCIETY OF HYPERTENSION. Kyoto, Japan, May 1988.) **Published:** *J Hypertension* 1988; 6(Suppl 4):S597-S601, as part of the meeting proceedings.
112. Daugherty SA, Borhani NO, on behalf of the HDFP. **Blood pressure and treatment patterns among HDFP participants during a two-year Post-Trial Surveillance study.** (Presented at the 12TH SCIENTIFIC MEETING OF THE INTERNATIONAL SOCIETY OF HYPERTENSION. Kyoto, Japan, May 1988.) **Abstract:** *J Hypertension* 1988; 6(Suppl 4):S750-S751.
113. HDFP Cooperative Group. **Persistence of reduction in blood pressure and mortality of participants in the Hypertension Detection and Follow-up Program.** **Abstract:** *Modern Medicine Abstracts* 1988; ??.
114. Moorman PG, Ford CE, Tyroler HA. **Educational level and all-cause mortality in the HDFP trial and Post-Trial Surveillance Study (PTSS).** (Presented at the 13TH SCIENTIFIC MEETING OF THE INTERNATIONAL SOCIETY OF HYPERTENSION, June 1990, in Montreal, Canada.)
115. Stamler R, Ford CE, Stamler J. **Why do lean hypertensives have higher mortality rates than average weight hypertensives? Findings from the Hypertension Detection and Follow-up Program.** (Presented at the 63RD SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION, November 1990, in Dallas, Texas.) **Abstract:** *Circulation* 1990; 82(Suppl III): III-554.
116. Curb JD, Pressel S, Daugherty S, Schneider K, Payne G, Ford C. **The relationship of white blood cell count to total and coronary heart disease mortality.** (Presented at the 63RD SCIENTIFIC SESSIONS OF THE AMERICAN HEART ASSOCIATION, November 1990, in Dallas, Texas.) **Abstract:** *Circulation* 1990; 82(Suppl III): III-616.
117. Ford CE, Davis BR, Hawkins CM, Stamler J, Curb JD, Daugherty S, Borhani NO, Payne GH, Langford HG, Remington RD. **The effect of treatment on combined endpoints in the Hypertension Detection and Follow-up Program (HDFP).** (Presented at the 31ST ANNUAL CONFERENCE ON CARDIOVASCULAR DISEASE EPIDEMIOLOGY, March 14, 1991, in Orlando, Florida.) **Abstract:** *Circulation* 1991; 83:716.